The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 64 results
Sort by date: Descending
Encores: Not included
Sleep-wake disorders
SLEEP 2026 PRESENTATION
Vibrance-2: A Randomized Phase 2 Study Evaluating Efficacy and Safety of the Orexin 2 Receptor Agonist Alixorexton in Patients With Narcolepsy Type 2
AUTHOR(S)

Richard K. Bogan,1 Giuseppe Plazzi,2,3 Emmanuel Mignot,4 Rafael del Río Villegas,5,6 Bruce Corser,7 Brendon J. Yee,8 Diego García-Borreguero,9 Chad Ruoff,10 David T. Plante,11 Hailu Chen,12 Alexandra Lovett,12 Michael J. Doane,12 Craig Hopkinson,12 Bhaskar Rege,12 Julie Himes12

View presentation
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Polysomnographic Findings in Pediatric Patients With Narcolepsy Type 1 and Narcolepsy Type 2: A Retrospective Review
AUTHOR(S)

Sally Ibrahim, MD1,2; Kiran Maski, MD, MPH3; Anne Marie Morse, DO4; Rakesh Bhattacharjee, MD5; Judith Owens, MD3; Luis E. Ortiz, MD6; Gary Feldman, MD7; Narong Simakajornboon, MD8; Joshua Henderson, BA9; Jennifer Gudeman, PharmD10,a; Brian Abaluck, MD11; Femida H. Gwadry-Sridhar, RPh, PhD9 
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Improvements in Quality of Life in Patients With Narcolepsy Type 1 Treated With the Orexin 2 Receptor Agonist Alixorexton
AUTHOR(S)

Gert Jan Lammers,1,2 Yves Dauvilliers,3 Ronald R. Grunstein,4,5 Emmanuel Mignot,6 David T. Plante,7 Erik Buntinx,8 Rafael del Río Villegas,9,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 Giuseppe Plazzi12,13 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Oxybate Treatment Experience and Preferences of People With Idiopathic Hypersomnia
AUTHOR(S)

John C. Carter, MD1,2; Anne Marie Morse, DO3; Michael J. Thorpy, MD4; Bruce C. Corser, MD5; Sally Ibrahim, MD1,6; Maria Picone7; Angeni Cordova, MPH7; Lauren Dougherty7; Jacqueline Brooks, MBBCh, MRCPsych8; Jennifer Gudeman, PharmD9,a 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Impact of Economic Status Across Race and Ethnicity on Narcolepsy Treatment Access: A Claims Database Analysis
AUTHOR(S)

Rakesh Bhattacharjee, MD1; Alec B. Platt, MD, MSCE2; Heidy Merius, DNP3,4; Omavi Bailey, MD, MPH5; Jennifer Gudeman, PharmD6,a; Johanna Hertel, PhD7; Brian Abaluck, MD7

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Treatment Access for Narcolepsy Across Patient Demographic Characteristics: A Claims Database Analysis
AUTHOR(S)

Alec B. Platt, MD, MSCE1; Rakesh Bhattacharjee, MD2; Maggie Lavender, MSN, RN, FNP-C3,4; Amber Burns, PA-C5; Jennifer Gudeman, PharmD6,a; Johanna Hertel, PhD7; Brian Abaluck, MD7
 

View poster
Sleep-wake disorders